Treatments for childhood leukemia that has returned
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study looks at different treatments for children whose leukemia (B-cell acute lymphoblastic leukemia) has returned after initial treatment. It tests new drug combinations and compares them to standard chemotherapy to find the best way to put the cancer back into remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The patient is between 1 and 20 years old.
- The leukemia has come back for the first time (first relapse).
- The relapse is not after a prior stem cell transplant or CAR-T cell therapy.
- The leukemia is a type called B-cell acute lymphoblastic leukemia (ALL).
- The patient is enrolled at a participating study center.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
This Phase 2 study tests a treatment approach for children with high-risk ALL that has returned. It aims to improve outcomes after relapse by using a planned treatment schedule.
This trial tests a combination of two treatments—blinatumomab and a special type of immune cell called iNKT—to fight B-cell acute lymphoblastic leukemia (ALL) that has returned or is not responding well after prior treatment. The goal is to see if this combination is safe and effective for patients who have had a relapse or new minimal residual disease (MRD) after previous treatment.
This trial tests a combination of three drugs (Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone) for children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after treatment. It may help those whose leukemia has not responded to standard therapy or who have relapsed after a stem cell transplant or CAR-T therapy.
Hear when a new B-Cell Acute Lymphoblastic Leukaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.